Watson Pharmaceuticals, Inc. confirmed that it has filed with the FDA an Abbreviated New Drug Application (ANDA) for Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0mg/0.02mg/0.451mg and Levomefolate Calcium Tablets, 0.451mg, a generic version of Bayer HealthCare Pharmaceuticals Inc.’s Beyaz.
Inflammatory skin conditions, including plaque psoriasis (PP), dermatitis, lichen planus (LP), and pityriasis rosea (PR), each exhibit a characteristic dermoscopic pattern.
Mylan announced that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) for Doxycycline hyclate delayed-release tablets USP, 150mg.
Sanofi announced that the FDA has approved Sklice (ivermectin lotion) 0.5% for the topical treatment of head lice in patients ≥6 months of age.
Cleaning the umbilical cord with chlorhexidine after birth significantly reduces newborn mortality and infection in rural Bangladesh and Pakistan.
Mylan announced that it has acquired the abbreviated new drug application (ANDA) for Clindamycin Phosphate / Benzoyl Peroxide gel, the generic version of Valeant’s BenzaClin, and a license to manufacture and market Fluorouracil 5%, the generic version of Valeant’s Efudex Cream.
Genentech announced that the FDA has approved Erivedge (vismodegib capsules) for the treatment of adults with advanced basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.
LEO Pharma announced that the FDA has approved Picato (ingenol mebutate gel) for the topical treatment of actinic keratosis.
Use of a chlorhexidine-based solution for preoperative skin marking is associated with more erasure of skin markings than an iodine-based alternative.
The long-term efficacy of adalimumab is well maintained in patients who experience an initial response of 75% or greater improvement in the Psoriasis Area and Severity Index score (PASI 75).
